NEW YORK, May 14, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ: NMRA) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Neumora Therapeutics caused the company to misrepresent or fail to disclose (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two Trial in ...

On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-2025 Secured $125 million venture debt facility from K2 HealthVentures, with $40 million available in 2025; cash runw ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Q4 2024 Results Conference Call March 3, 2025 8:00 AM ET Company Participants Helen Rubinstein - Vice President of Investor Relations & Communications Paul Berns - Chief Executive Officer Josh Pinto - President Bill Aurora - Chief Operating & Development Officer Michael Milligan - Chief Financial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Douglas Tsao - H.C. Wainwright Delma Caiati - Guggenheim Paul Matteis - Stifel Sam Lee - Mizuho Tes ...